



HUTCHISON CHINA MEDITECH LIMITED

**Hutchison China MediTech Limited (“Chi-Med”)
(AIM: HCM)**

Directors’ Shareholding

London: Wednesday, 1 April 2015: Chi-Med received notifications on 1 April 2015 that the following Directors have purchased ordinary shares of US\$1.00 each in Chi-Med (the “Shares”) as follows:-

Director	Date of purchase	Number of Shares purchased	Purchase price	Beneficial interest in Shares following purchases	
				Number of Shares	% of total issued share capital
Simon To (Executive Director and Chairman)	30 March 2015	13,000	GBP13.00	69,000	0.13%
	1 April 2015	15,000	GBP13.65		
Edith Shih (Non-executive Director and Company Secretary)	30 March 2015	13,000	GBP13.00	48,000	0.09%
	1 April 2015	15,000	GBP13.65		

Ends

Enquiries

Chi-Med
Christian Hogg, CEO

Telephone: +852 2121 8200

Panmure Gordon (UK) Limited
Richard Gray
Andrew Potts

Telephone: +44 20 7886 2500

Citigate Dewe Rogerson
Anthony Carlisle
David Dible

Telephone: +44 20 7638 9571
Mobile: +44 7973 611 888
Mobile: +44 7967 566 919

About Chi-Med

Chi-Med is a China-based healthcare group focused on researching, developing, manufacturing and selling pharmaceuticals and health-related consumer products. Its Drug R&D Division focuses on discovering and developing innovative therapeutics in oncology and autoimmune diseases. Its China Healthcare Division manufactures, markets and distributes prescription and over-the-counter pharmaceuticals in China. Its emerging Consumer Products Division focuses on organic and natural consumer products in Asia.

Chi-Med is majority owned by the multinational conglomerate Hutchison Whampoa Limited (SEHK:13). For more information, please visit: www.chi-med.com.